(Boursier.com) — NOXXON Pharma has drawn additional tranches of funding from its funding agreement with Atlas Special Opportunities, LLC (ASO), for a total amount of €2.375 million. This resulted in the issuance of 2,419 convertible bonds (including the 44 convertible bonds issued in connection with transaction costs) with a nominal value of 1,000 euros each.
NOXXON believes that the remaining availability under the agreement with ASO extends its financial visibility until December 2022.
©2022 Boursier.com